SCHEMBL3660477

SCHEMBL3660477

COc1ccc(OC)c(C(C)C(C(=O)O)C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.54
CYP2D6 P10635 2/20 0.54
ADRA2A P08913 2/20 0.54
MEN1 O00255 1/20 0.53
MAPK1 P28482 1/20 0.53
BLM P54132 1/20 0.53
KMT2A Q03164 1/20 0.53
HTT P42858 1/20 0.51
ADRB2 P07550 1/20 0.49
ADRB1 P08588 1/20 0.49
ADRB3 P13945 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
ACHE P22303 1/20 0.49
SCN1A P35498 1/20 0.48
SCN2A Q99250 1/20 0.48
SCN3A Q9NY46 1/20 0.48
HSD17B10 Q99714 1/20 0.47
RAB9A P51151 1/20 0.47
CYP1A2 P05177 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28815671 0.87 PTGS2 (0.46) ADRA1ACYP2D6ADRA2AMEN1KMT2A
SCHEMBL491187 0.83 PTGS2 (0.61) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL31512445 0.83 PTGS2 (0.61) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL7060376 0.82 CYP2D6 (0.51) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL7059386 0.80 TDP1 (0.47) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL28936060 0.79 ADRA1A (0.65) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL23414454 0.79 ADRA1A (0.59) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL27644642 0.79 ADRA1A (0.52) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL7061295 0.79 ADRA1A (0.47) ADRA1ACYP2D6ADRA2AMEN1MAPK1
SCHEMBL28027161 0.78 ADRA1A (0.58) ADRA1ACYP2D6ADRA2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937152-B2 Non-selective somatostatin analogues ITALFARMACO SPA (IT) 2015-01-20 US disclosed
EP-2225271-B1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2013-07-31 EP disclosed
US-20100323964-A1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2010-12-23 US disclosed
EP-2225271-A2 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO S.p.A. (IT) 2010-09-08 EP disclosed
WO-2009071460-A2 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2009-06-11 WO disclosed
EP-2067786-A1 Novel non selective analogs of somatostatin ITALFARMACO S.p.A. (IT) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100323964-A1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES SSTR4, SSTR1, SSTR3 ADRA1A 907/4885CYP2D6 4226/4885ADRA2A 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.